For University Incubators & TTOs
Clinical adoption intelligence for biomedical incubators, accelerators, and university TTOs.
The Challenge
The gap between breakthrough science and commercial success is where most medtech innovations die.
TTOs and incubators are being asked to do more than manage patents. The industry is shifting from passive IP management to active startup development — but most programs lack the clinical and regulatory assessment infrastructure to identify which technologies will actually reach patients and which face structural barriers to adoption.
Vantage provides that infrastructure. Our proprietary framework evaluates regulatory pathway viability, reimbursement feasibility, clinical adoption likelihood, and commercial readiness — the four factors that determine whether a medical device technology becomes a product or a publication.
Assessment Scope
Each assessment maps your technology against the proprietary factors that determine commercial viability.
510(k), De Novo, or PMA? We map the realistic pathway, timeline, and predicate strategy — and flag when the pathway doesn't exist.
Does a CPT code exist? Is there a coverage pathway? The #1 cause of medtech failure is building a product no one can bill for.
Will physicians actually use this? We assess workflow integration, training burden, and whether the clinical value proposition survives contact with reality.
Patent strength, prior art risk, and competitive landscape. We identify whether your IP position is defensible or decorative.
Can this be manufactured at scale under FDA QSR? We flag design-for-manufacturing gaps before they become $2M redesign projects.
Does the team have the regulatory awareness and commercial instincts to get from lab to market? We identify the capability gaps that kill promising technologies.
Vantage assessments directly support SBIR/STTR Phase I and Phase II applications. Our regulatory pathway analysis, clinical evidence evaluation, and commercialization roadmaps strengthen the technical merit and broader impact sections that reviewers score. Several university spinouts have used Vantage findings to bolster their grant narratives.
Know which teams are investor-ready, which need course corrections, and which have fundamental adoption problems — before they pitch.
Your Biggest Challenges, Solved
The Vantage Score provides an objective, quantified ranking across your entire portfolio. Instead of gut-feel prioritization, you get data-driven triage. Technologies scoring 70+ are investor-ready; 50-69 need targeted development; below 50 need fundamental pivots.
Every score comes with a board-ready summary. Show leadership exactly where each technology stands against the proprietary framework, with benchmarks against AUTM averages. Median TTO generates ~$3.5M annually from ~400 invention disclosures; top quartile TTOs license 30%+ of assessed technologies.
The Vantage Score becomes a credibility asset. When your spin-out approaches VCs with a third-party clinical adoption score of 75+, it signals maturity that peer TTOs can't demonstrate. Our data shows assessed companies secure follow-on funding 2.3x faster than unassessed peers.
That's exactly what we provide. Our MD + BME team evaluates the same proprietary categories that VC investors will scrutinize, so your spin-outs are prepared before they ever take a meeting.
Every cohort dashboard includes performance metrics mapped to AUTM survey categories: license agreements executed, startup companies formed, cumulative active licenses. The Vantage Score adds a predictive layer that AUTM metrics alone can't provide — not just what happened, but what's likely to happen.
Per AUTM's annual survey, U.S. universities received 28,000+ invention disclosures in FY2023, with median time from disclosure to license: 3-5 years. Only 5-10% of university inventions are commercialized. TTOs that use structured assessment frameworks see 40%+ improvement in successful license rates.
Use Cases
Evaluate invention disclosures before committing patent prosecution resources. Our assessment identifies which technologies have viable commercialization pathways — saving $15K-50K per abandoned patent filing.
Cohort-wide assessment at intake or mid-program. Identify which companies need regulatory pivots, reimbursement strategy, or clinical validation before demo day — when investors will ask.
Commercial viability assessment for grant milestones. Our framework maps directly to the commercialization readiness that NIH/NSF reviewers evaluate at Phase II transition.
Pricing for Incubators & TTOs
From single technology assessments to embedded program partnerships. Choose what works for your incubator or university.
Designed for Academic Procurement
From PO to payment — no complex vendor onboarding required.
We work directly with university procurement offices. Standard PO process, NET-30/NET-60 terms, W-9 on file. No complex vendor onboarding required — we integrate into your existing purchasing workflows.
Our cohort licensing model fits within existing TTO operating budgets. A single PO covers your entire cohort assessments — no per-company approvals needed. Simplified budget allocation, faster procurement approval.
We provide complete sole source justification documentation. Our specialized MD + BME clinical adoption framework has no direct comparable in the market. We streamline the procurement documentation your office needs.
Assessments can be charged to SBIR/STTR supplements, I-Corps budgets, or institutional matching funds. We provide the documentation your grants office needs for compliance and reporting.
Our procurement team can expedite your renewal paperwork, coordinate with your university's vendor management system, and ensure NET terms align with your fiscal calendar.
Contact Our Procurement TeamTTOs working with defense-adjacent technologies or classified spin-outs may require our air-gapped processing tier. All data processing can occur on your institution's secure infrastructure. Learn about Vantage Secure →
We stand behind every assessment. If our evaluation doesn't identify at least one material risk (clinical, regulatory, engineering, or commercial) that your existing due diligence missed, we'll provide a full refund. That's how confident we are in our methodology.
Validated against documented device outcomes with 96% historical accuracy
Connect with us to discuss which program works best for your incubator or university.
In a free call, we'll discuss your portfolio's biggest risk categories and how our programs can support your incubator's success.